血小板反应蛋白2在恶性肿瘤中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.12.1881

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (12): 1881-1885.doi: 10.16352/j.issn.1001-6325.2023.12.1881

血小板反应蛋白2在恶性肿瘤中作用的研究进展

马郏俊延^1,2, 芮天楠^1,2, 张永胜^1*

1.苏州大学附属第二医院病理科,江苏苏州 215004;
2.苏州大学苏州医学院临床医学系,江苏苏州 215123

收稿日期:2023-04-26 修回日期:2023-09-28 出版日期:2023-12-05 发布日期:2023-11-29
通讯作者: ^* shengyongzh@126.com
基金资助:
国家自然科学基金(12275192);苏州大学学生课外科研项目(2021YXBKWKY057)

Research progress on the role of thrombospondin 2 in malignant tumors

MA Jiajunyan^1,2, RUI Tiannan^1,2, ZHANG Yongsheng^1*

1. Department of Pathology, the Second Affiliated Hospital of Soochow University, Suzhou 215004;
2. Department of Clinical Medicine, Suzhou Medical College, Soochow University, Suzhou 215123, China

Received:2023-04-26 Revised:2023-09-28 Online:2023-12-05 Published:2023-11-29
Contact: ^* shengyongzh@126.com

摘要/Abstract

摘要： 血小板反应蛋白2(THBS2)是一种基质细胞钙结合糖蛋白,能与细胞外基质和细胞表面的多种生长因子、受体、基质分子或蛋白酶等相互作用。THBS2可在N⁶-甲基腺苷RNA甲基化酶作用下活化,并通过重塑肿瘤微环境以及参与多条细胞信号通路等方式介导肿瘤增殖、迁移与侵袭。THBS2可作为多种肿瘤的诊断和预后指标,并有望成为肿瘤治疗新靶点。

关键词: 血小板反应蛋白, 血小板反应蛋白2, 肿瘤

Abstract: Thrombospondin 2 (THBS2) is a matrix cell calcium-binding glycoprotein that interacts with a variety of growth factors, receptors, matrix molecules or proteases on the extracellular matrix and cell surface. THBS2 can be activated by N⁶-methyladenosyl RNA methylase, and mediates tumor proliferation, migration and invasion by remodeling the tumor microenvironment and participating in multiple cell signaling pathways. THBS2 could be used as a diagnostic and prognostic indicator for a variety of tumors, and is expected to become a new target for malignant tumor treatment.

Key words: thrombospondin, thrombospondin 2, carcinoma

中图分类号:

R730.2

马郏俊延, 芮天楠, 张永胜. 血小板反应蛋白2在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2023, 43(12): 1881-1885.

MA Jiajunyan, RUI Tiannan, ZHANG Yongsheng. Research progress on the role of thrombospondin 2 in malignant tumors[J]. Basic & Clinical Medicine, 2023, 43(12): 1881-1885.

参考文献 27

[1]	Zou S, Li J, Yan J, et al. Distribution of serum thrombospondin-2, a novel tumor marker, in general population and cancer patients in China[J]. Clin Chim Acta, 2021, 518: 123-127.
[2]	Calabro NE, Kristofik NJ, Kyriakides TR. Thrombos-pondin-2 and extracellular matrix assembly[J]. Biochim Biophys Acta, 2014, 1840: 2396-2402.
[3]	Hou CH, Tang CH, Chen PC, et al. Thrombospondin 2 promotes IL-6 production in osteoarthritis synovial fibroblasts via the PI3K/AKT/NF-κB pathway[J]. J Inflamm Res, 2021, 14: 5955-5967.
[4]	Wang W, He Y, Wu L, et al. N(6) -methyladenosine RNA demethylase FTO regulates extracellular matrix-related genes and promotes pancreatic cancer cell migration and invasion[J]. Cancer Med, 2023, 12: 3731-3743.
[5]	Liao X, Wang W, Yu B, et al. Thrombospondin-2 acts as a bridge between tumor extracellular matrix and immune infiltration in pancreatic and stomach adenocarcinomas: an integrative pan-cancer analysis[J]. Cancer Cell Int, 2022, 22: 213. doi: 10.1186/s12935-022-02622-x.
[6]	Shi M, Gu Y, Jin K, et al. CD47 expression in gastric cancer clinical correlates and association with macrophage infiltration[J]. Cancer Immunol Immunother, 2021, 70: 1831-1840.
[7]	Hsieh RC, Krishnan S, Wu RC, et al. ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colore-ctal cancer[J]. Sci Immunol, 2022, 7: eabl9330. doi: 10.1126/sciimmunol.abl9330.
[8]	Qu HL, Hasen GW, Hou YY, et al. THBS2 promotes cell migration and invasion in colorectal cancer via modulating Wnt/β-catenin signaling pathway[J]. Kaohsiung J Med Sci, 2022, 38: 469-478.
[9]	Deng B, Liu XP, Wang X. Prognostic and Immunologi-cal Role of THBS2 in Colorectal cancer[J]. Biomed Res Int, 2021, 2021: 1124985. doi: 10.1155/2021/1124985.
[10]	Xu C, Gu L, Kuerbanjiang M, et al. Thrombospondin 2/Toll-Like Receptor 4 Axis Contributes to HIF-1 alpha-Derived Glycolysis in Colorectal Cancer[J]. Front Oncol, 2020, 10: 557730. doi: 10.3389/fonc.2020.557730.
[11]	Slattery ML, Mullany LE, Sakoda LC, et al. The PI3K/AKT signaling pathway: Associations of miRNAs with dysregulated gene expression in colorectal cancer[J]. Mol Carcinog, 2018, 57: 243-261.
[12]	Deng B, Liu XP, Wang X. Prognostic and Immunological Role of THBS2 in Colorectal cancer[J]. Biomed Res Int, 2021, 2021: 1124985. doi: 10.1155/2021/1124985.
[13]	Nan P, Dong X, Bai X, et al. Tumor-stroma TGF-beta1-THBS2 feedback circuit drives pancreatic ductal adenocarcinoma progression via integrin alphavbeta3/CD36-mediated activation of the MAPK pathway[J]. Cancer letters, 2022, 528: 59-75.
[14]	Le Large TYS, Meijer LL, Paleckyte R, et al. Combined expression of plasma thrombospondin-2 and CA19-9 for diagnosis of pancreatic cancer and distal cholangiocar-cinoma: a proteome approach[J]. Oncologist, 2020, 25: e634-e643.
[15]	Byrling J, Hilmersson KS, Ansari D, et al. Thrombospondin-2 as a diagnostic biomarker for distal cholangiocarcinoma and pancreatic ductal adenocarcinoma[J]. Clin Transl Oncol, 2022, 24: 297-304.
[16]	Gimotty PA, Till JE, Udgata S, et al. THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma[J]. Oncotarget, 2021, 12: 2266-2272.
[17]	Bao Y, Yan E, Wang N. Evaluation of GREM1 and THBS2 as prognostic markers in in non-small cell lung cancer[J]. J Cancer Res Clin Oncol, 2023, 149: 7849-7856.
[18]	Liu JF, Lee CW, Tsai MH, et al. Thrombospondin 2 promotes tumor metastasis by inducing matrix metalloproteinase-13 production in lung cancer cells [J]. Biochem Pharmacol, 2018, 155: 537-546.
[19]	Wang L, Zhao L, Wang Y. Circular RNA circ_0020123 promotes non-small cell lung cancer progression by sponging miR-590-5p to regulate THBS2[J]. Cancer Cell Int, 2020, 20: 387. doi: 10.1186/s12935-020-01444-z.
[20]	Yang Z, Wu H, Zhang K, et al. Circ_0007580 knockdown strengthens the radiosensitivity of non-small cell lung cancer via the miR-598-dependent regulation of THBS2[J]. Thorac Cancer, 2022, 13: 678-689.
[21]	Li X, Wu F. Mesenchymal stem cell-derived extracellular vesicles transfer miR-598 to inhibit the growth and metastasis of non-small-cell lung cancer by targeting THBS2[J]. Cell Death Discov, 2023, 9: 3. doi: 10.1038/s41420-022-01283-z.
[22]	Wang L, Feng L, Liu L, et al. Joint effect of THBS2 and VCAN accelerating the poor prognosis of gastric cancer[J]. Aging (Albany NY), 2023, 15: 1343-1357.
[23]	Grunberg N, Pevsner-Fischer M, Goshen-Lago T, et al. Cancer-associated fibroblasts promote aggressive gastric cancer phenotypes via heat shock factor 1-mediated secretion of extracellular vesicles[J]. Cancer Res, 2021, 81: 1639-1653.
[24]	Chu XD, Lin ZB, Huang T, et al. Thrombospondin-2 holds prognostic value and is associated with metastasis and the mismatch repair process in gastric cancer[J]. BMC Cancer, 2022, 22: 250. doi: 10.1186/s12885-022-09201-3.
[25]	Shi H, Qi C, Meng L, et al. Bone marrow-derived mesenchymal stem cells promote Helicobacter pylori-associated gastric cancer progression by secreting thrombospondin-2[J]. Cell Prolif, 2021, 54: e13114. doi: 10.1111/cpr.13114.
[26]	Carpino G, Cardinale V, Di Giamberardino A, et al. Thrombospondin 1 and 2 along with PEDF inhibit angiogenesis and promote lymphangiogenesis in intrahe-patic cholangiocarcinoma[J]. J Hepatol, 2021, 75: 1377-1386.
[27]	Carvalho RF, do Canto LM, Abildgaard C, et al. Single-cell and bulk RNA sequencing reveal ligands and receptors associated with worse overall survival in serous ovarian cancer[J]. Cell Commun Signal, 2022, 20: 176. doi: 10.1186/s12964-022-00991-4.

血小板反应蛋白2在恶性肿瘤中作用的研究进展

Research progress on the role of thrombospondin 2 in malignant tumors

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	夏雨佳, 杨振丽, 刘玉琴. 肿瘤类器官临床前转化研究及应用[J]. 基础医学与临床, 2024, 44(9): 1214-1218.
[2]	刘保清, 黄容, 卢艳, 李凯, 张宁, 刘长征, 宋伟. 胃癌类器官在基础研究与临床应用中的进展[J]. 基础医学与临床, 2024, 44(9): 1219-1222.
[3]	李阳, 朱蕾. 真核延伸因子2激酶是治疗肿瘤的潜在新靶标[J]. 基础医学与临床, 2024, 44(7): 1039-1043.
[4]	陈笑天, 陈翀, 罗云萍. MAFB对肿瘤相关巨噬细胞极化及功能的影响[J]. 基础医学与临床, 2024, 44(7): 965-973.
[5]	谭树芬, 何利平, 杨琳琳, 杨谢兰, 杨宏英, 姚明姣, 李树清. TBL与工作坊整合教学法在妇科肿瘤学临床教学中的应用[J]. 基础医学与临床, 2024, 44(7): 1054-1057.
[6]	周玥, 童安莉. 嗜铬细胞瘤/副神经节瘤免疫微环境[J]. 基础医学与临床, 2024, 44(6): 742-747.
[7]	张沥元, 杜函泽, 潘慧. 治疗下丘脑性肥胖的药物研究进展[J]. 基础医学与临床, 2024, 44(5): 729-732.
[8]	王婷婷, 郭丹, 陆君阳, 徐徕, 董海涛, 林佃新, 肖毅. 结直肠神经内分泌肿瘤细胞突变类型分析[J]. 基础医学与临床, 2024, 44(4): 523-527.
[9]	王子豪, 夏小超, 李舜. 跨膜蛋白质在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 398-402.
[10]	吴玉红, 喻才元, 叶石才. NMES1基因在恶性肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(3): 403-407.
[11]	南璐, 郭梦杰, 高雅楠, 贾红燕. 膜联蛋白A家族成员在乳腺癌中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(3): 393-397.
[12]	陈雪, 罗添, 魏超君. 溶血磷脂酰胆碱酰基转移酶1在肿瘤中作用的研究进展[J]. 基础医学与临床, 2024, 44(2): 256-259.
[13]	刘宛榕, 赵林. 颅内生殖细胞肿瘤的药物治疗[J]. 基础医学与临床, 2024, 44(10): 1350-1356.
[14]	刘林弟, 吕庆杰. GPSM2在肿瘤中作用机制的研究进展[J]. 基础医学与临床, 2024, 44(10): 1447-1450.
[15]	李文超, 李祥生, 李富光, 张志永, 惠磊, 周文科. 长链非编码RNA与疾病[J]. 基础医学与临床, 2024, 44(10): 1465-1469.